Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open-label, single-arm study.
Ronit M PresslerGeraldine BoylanEugene DempseyKerstin Alexandra KlotzWalter KrauwinkelEdgar WillDiego MoritaFlorin FloricelJan-Peer ElshoffJohn van den AnkerPublished in: Epilepsia open (2023)
BRV plasma concentrations in neonates were consistent with data in older children receiving BRV oral solution, and with data from adults receiving a nominal IV dose of 25 mg twice daily. BRV was well-tolerated, with no drug-related TEAEs reported.